Skip to main content
Clinical Trials/NCT01917682
NCT01917682
Completed
Not Applicable

A Post-Market Registry for the Evaluation of the CorPath 200 System Effectiveness in Percutaneous Coronary Interventions

Corindus Inc.16 sites in 2 countries754 target enrollmentAugust 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Corindus Inc.
Enrollment
754
Locations
16
Primary Endpoint
Number of Participants With Clinical Success
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

To collect data on the routine patterns of use, safety and effectiveness, including the clinical and technical performance of the CorPath 200 System, in the delivery and manipulation of coronary guidewires and stent/balloon catheters during PCI procedures.

Detailed Description

This is a prospective, single-arm, open-label, multi-center patient registry of the CorPath 200 System to examine its performance during PCI procedure and patient outcomes through 72 hours post-procedure or hospital discharge, whichever occurs first.

Registry
clinicaltrials.gov
Start Date
August 2013
End Date
December 2016
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age \>18 years.
  • Patients with coronary artery disease undergoing Percutaneous Coronary Intervention (PCI) with the CorPath 200 system.
  • The subject or the legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.

Exclusion Criteria

  • Concurrent enrollment in another device or drug study protocol that specifically excludes concurrent enrollment or that prevents collection of data required in this registry (concurrent participation in another registry is not an automatic exclusion criterion for this study).
  • Failure/inability/unwillingness to provide informed consent.

Outcomes

Primary Outcomes

Number of Participants With Clinical Success

Time Frame: In-hospital (72-hours or discharge, whichever occurs first)

Less than 30% residual stenosis post PCI in the lesion(s) treated with the CorPath system, without in-hospital major adverse coronary events (MACE).

Secondary Outcomes

  • Number of Participants With In-hospital Major Adverse Coronary Events (MACE)(In-hospital (72-hours or discharge, whichever occurs first))
  • Number of Participants With an Adverse Event(In-hospital (72-hours or discharge, whichever occurs first))

Study Sites (16)

Loading locations...

Similar Trials